Cardiome Pharma (CRME) Tops Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Cardiome Reports Third Quarter 2016 Financial Results
November 7, 2016 8:00 AM ESTCardiome to conduct conference call and webcast on Monday, November 7, 2016 at 4:00pm Eastern (1:00pm Pacific)
NASDAQ: CRME TSX: COM
Quarterly Highlights:
Q3 revenue consistent with both quarterly and annual targets. Completed an underwritten equity offering whereby Cardiome issued 11.5 million shares from treasury for gross proceeds of US$34.5 million. Prepared our commercial markets for the imminent launch of XYDALBA. Initiated commercial operations in Canada by putting an acute-care hospital focused sales force in place. Announced that the European Medicines Agency had approved... More